Time-to-event analyses for long-term treatments--the APPROVe trial.
Lagakos
Stephen W
SW
Harvard School of Public Health, Boston, USA.
D018256:Adenomatous Polyps / Q000517:prevention & control*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D003627:Data Interpretation, Statistical; D005500:Follow-Up Studies; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D013450:Sulfones / Q000009:adverse effects*; D016019:Survival Analysis; D013927:Thrombosis / Q000139:chemically induced; D013997:Time Factors
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib